Spruce Biosciences, Inc. (NASDAQ:SPRB) Director Bali Muralidhar purchased 200,000 shares of Spruce Biosciences stock in a transaction dated Wednesday, October 14th. The stock was bought at an average price of $15.00 per share, with a total value of $3,000,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of NASDAQ SPRB opened at $15.38 on Friday. Spruce Biosciences, Inc. has a fifty-two week low of $15.12 and a fifty-two week high of $18.49.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH.

Featured Story: How Investors Use a Balance Sheet

Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.